Jagsonpal Pharmaceuticals is acquiring an 85% stake in Aequitas Healthcare Private Limited for ₹20.8 crore cash. This move aims to enter the hospital and institutional sales channel, transitioning the company to an omnichannel model.
Jagsonpal Pharmaceuticals Acquires 85% Stake in Aequitas Healthcare
Jagsonpal Pharmaceuticals announced the acquisition of an 85% stake in Aequitas Healthcare Private Limited for ₹20.8 crore. The company will fund this acquisition entirely through internal accruals.
What just happened
Jagsonpal Pharmaceuticals is acquiring 85% of Aequitas Healthcare Private Limited for ₹20.8 crore in cash. This strategic move is intended to gain entry into the hospital channel and institutional doctor network. The transaction is expected to be completed by July 15, 2026.
Why this matters
This acquisition signifies a strategic shift for Jagsonpal Pharmaceuticals, moving from a retail prescription focus to an omnichannel specialty healthcare business. Gaining immediate access to leading hospital chains in India through Aequitas is expected to accelerate growth in a key segment contributing around 10% of industry sales.
The backstory
Aequitas Healthcare Private Limited has shown consistent revenue contributions, with figures ranging from ₹53.31 crore in FY26 (target) to ₹53.71 crore in FY24. This indicates an established business in its domain.
What changes now
The acquisition enables Jagsonpal to reduce the time needed to build institutional relationships organically. The focus will now be on integrating the hospital distribution channel and scaling this new segment as part of the company's omnichannel strategy.
Risks to watch
The primary risk lies in the successful integration of the acquired hospital channel and the execution of the post-acquisition business plan. Investors will be watching how effectively this new segment contributes to overall sales growth.
Peer comparison
While specific peer data is not provided in the filing, the move into the hospital channel is a common strategy for pharmaceutical companies seeking to diversify revenue streams beyond traditional retail prescriptions.
Context metrics (time-bound)
Aequitas Healthcare reported target revenues of ₹53.31 crore for FY2025-26, ₹56.19 crore for FY2024-25, and ₹53.71 crore for FY2023-24. The acquisition is planned for completion by July 15, 2026.
What to track next
Investors should monitor the progress of the Share Purchase Agreement (SPA) finalization and the deal closure by the July 15, 2026 deadline. Post-closure, tracking management's commentary on the hospital channel's contribution to sales will be crucial.
Reader Takeaway: Inorganic growth into the hospital segment funded by internal cash, watch integration and scaling.